13F Data
13F filer · CIK 1953107

ENAVATE SCIENCES GP, LLC

New York, NY · filing since Q4 2024 · last filing Aug 14, 2026
Reported value
$345.4M
$-6.1M vs prior
Positions
7
New / sold out
0 / 0
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $3.3M
Top-10 weight
100.0%

Biggest buys vs Q1 2026

No new or increased positions this quarter.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedCAMP4 THERAPEUTICS CORP-765,379-34.9%$-3.3M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2024: $139.2MQ1 2025: $132.7MQ2 2025: $176.5MQ3 2025: $327.5MQ4 2025: $506.8MQ1 2026: $351.5MQ2 2026: $345.4M
Q4 2024Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1SIONNA THERAPEUTICS INCCOM2,478,030$109.0M31.56%
2ZENAS BIOPHARMA INCCOM3,919,159$99.5M28.80%
3IMMUNOME INCCOM3,613,799$76.6M22.17%
4BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW2,626,946$20.0M5.80%
5COMPASS THERAPEUTICS INCCOM7,788,150$17.1M4.94%
6UPSTREAM BIO INCCOM2,459,703$17.0M4.93%
7CAMP4 THERAPEUTICS CORPCOM1,425,541$6.2M1.80%